Welcome to our dedicated page for Dariohealth news (Ticker: DRIO), a resource for investors and traders seeking the latest updates and insights on Dariohealth stock.
DarioHealth Corp. develops digital health and digital therapeutics solutions for people managing chronic conditions. The company’s multi-condition platform uses data analytics, connected health devices, personalized interventions and one-on-one coaching across diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
DRIO news commonly covers quarterly financial results, conference calls, commercial activity with health plans, payers, self-insured employers, care providers and consumers, and clinical research based on real-world platform data. Other recurring updates include AI-enabled product development such as DarioIQ, evidence publications, board and governance changes, and capital or credit arrangements supporting the company’s digital health business.
DarioHealth (NASDAQ: DRIO) has priced a registered direct offering of 3,454,559 shares of common stock (or equivalents) at $6.80 per share, structured as an at-the-market transaction under Nasdaq rules. Expected gross proceeds are approximately $23.5 million before placement fees and expenses, with closing targeted on or about July 23, 2026 subject to customary conditions.
A member of the board of directors is participating by purchasing 14,430 shares at $6.93 per share. According to DarioHealth, net proceeds are intended for working capital, investments, acquisitions and general corporate purposes. The securities are being issued off an effective Form S-3 shelf registration (File No. 333-294454), with A.G.P./Alliance Global Partners acting as sole placement agent. The company highlights participation from existing long-term institutional investors alongside a new global fundamental institutional investor.
DarioHealth (NASDAQ: DRIO) announced that a Fortune 50 employer has awarded the company a contract to provide its integrated, AI-powered digital cardiometabolic care platform for employees with diabetes and/or hypertension. The program will cover more than 100,000 eligible employees and is expected to launch in Fall 2026.
According to DarioHealth, annual recurring revenue from this program is expected to begin by year-end 2026 and increase through 2027 and beyond. This is Dario’s fifth Fortune 50 client, and nearly one-quarter of its clients are Fortune 500 companies. The platform targets comorbid chronic conditions using connected devices, human coaching and AI-driven insights via DarioIQ.
DarioHealth (NASDAQ: DRIO) announced that broader deployment of its proprietary AI engine DarioIQ™ is expected to increase annual B2B2C recurring revenue from existing customers by approximately 10%–15%, excluding any impact from future customer wins or condition expansions.
According to DarioHealth, DarioIQ’s AI-driven personalization increased active member engagement by 40% and improved member retention by 20% versus a control group, based on development completed in the first half of 2026. The company reports a program ROI of 2.5x–5x across its solutions.
DarioIQ uses more than 13 billion de-identified proprietary real-world healthcare data points, combining biometric readings from FDA-cleared devices, clinical history and behavioral patterns to optimize outreach. DarioHealth highlights responsible-AI practices and notes that its recent expansion into provider-backed care is expected to connect AI-driven engagement more directly to clinical intervention and reimbursement workflows.
DarioHealth (NASDAQ: DRIO) announced a new agreement with a major Arizona health insurer through its Amwell partnership, making its cardiometabolic digital health solution available to the insurer's ASO employer clients, representing access to hundreds of thousands of covered lives.
The deal supports Dario's channel-led, capital-efficient growth model, expanding recurring revenue opportunities and leveraging a network reaching over 116 million covered lives, with an employer ROI of up to 5x reported in a Sanofi-funded study.
DarioHealth (NASDAQ: DRIO) announced that one of the 5 largest U.S. health insurers extended its agreement and added Dario’s AI-powered hypertension solution after success with its behavioral health program.
The expanded cardiometabolic rollout may roughly triple revenue opportunity from this client, with contributions expected in 2026 and greater impact from 2027. This is the third health plan to expand beyond an initial condition, supporting Dario’s multi-condition strategy. Dario now serves 12 health plans, including 3 national carriers, across 6 chronic condition solutions using Beluga-enabled care delivery.
DarioHealth (NASDAQ: DRIO) appointed former Humana Senior Vice President and Chief Compliance Officer Sean O'Reilly to its Advisory Board.
The move is intended to strengthen compliance, regulatory and payer expertise as Dario advances its AI-enabled digital health platform and channel partner-led growth with health plans, employers and providers.
Dario (NASDAQ: DRIO) announced a Collaborative Services Agreement with Beluga Health to deliver provider-backed, digitally enabled chronic care across all 50 states.
The integrated platform combines coaching, AI triage and Beluga’s physician network to monitor, detect and treat conditions including diabetes, hypertension, obesity, behavioral health and musculoskeletal issues, using one vendor relationship.
The partnership targets health plans, health systems, employers and public programs, with evidence from a JMIR study showing Dario users had 23% lower hospitalization rates and 26% lower total charges than matched usual-care patients.
DarioHealth (NASDAQ: DRIO) reported four new studies at the American Diabetes Association Scientific Sessions showing clinical and economic signals from its digital cardiometabolic platform.
Results included 0.23 fewer hospitalizations PPPY, 6.4%–14.3% 12‑month weight loss, and 44.8% of high‑risk diabetes users achieving ≥1% eA1c reduction.
DarioHealth (NASDAQ: DRIO) announced that Solera Health has expanded Dario's digital offerings to include a broader hypertension program, now covering pre-hypertensive members through Stage 2 hypertension.
This more than doubles Dario's addressable market within Solera's network, tying revenue to engagement, longitudinal outcomes and recurring, year-long member experiences.
DarioHealth (NASDAQ: DRIO) reported first quarter 2026 revenue of $5.6 million, up 6.7% sequentially but below $6.8 million a year earlier, mainly due to non-recurring prior pharma revenue. GAAP gross margin was 57%; operating expenses fell to $10.5 million (down 21% YoY), cutting operating loss to $7.3 million. Net loss was $8.2 million. Cash and short-term deposits totaled $20 million, with $6 million net cash used in operations. Channel partnerships provide access to over 116 million covered lives, with a new contract in progress that could raise reach above 175 million. DarioHealth added 10 new accounts and reported a $127 million pipeline across 241 active opportunities.